Je veux savoir à propos de…

9510

Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration Docket No. FDA2020N2030

Agency Information Collection Activities; Submission for Office of Management and Budget Review;
Comment Request; Application for Food and Drug Administration Approval To Market a New Drug AGENCY:

Food and Drug Administration,
HHS.
ACTION:

Notice.

The Food and Drug Administration FDA is announcing that a proposed collection of information has been submitted to the Office of Management and Budget OMB for review and clearance under the Paperwork Reduction Act of 1995.
DATES: Submit written comments including recommendations on the collection of information by March 18, 2021.
ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https
www.reginfo.gov/public/do/PRAMain.
Find this particular information collection by selecting Currently under ReviewOpen for Public Comments or by using the search function. The OMB
control number for this information collection is 09100001. Also include the FDA docket number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A12M, 11601
Landsdown St., North Bethesda, MD
20852, 3017965733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed collection of information to OMB for review and clearance.

khammond on DSKJM1Z7X2PROD with NOTICES

SUMMARY:

Application for FDA Approval To Market a New Drug; OMB Control No.
09100001Revision This information collection supports FDA regulations. Under section 505a of the Federal Food, Drug, and Cosmetic Act FD&C Act 21 U.S.C. 355a, a new drug may not be commercially marketed in the United States unless an approval of an application filed with FDA under section 505b or j of the FD&C Act is effective with respect to such drug. We have issued regulations
VerDate Sep<11>2014

17:04 Feb 12, 2021

Jkt 253001

in part 314 21 CFR part 314 to govern procedures and requirements for applications submitted in accordance with section 505. The regulations in subpart A 314.1 through 314.3 set forth general provisions, while regulations in subparts B and C
314.50 through 314.99 set forth content and format requirements for new drug applications NDAs and abbreviated new drug applications ANDAs respectively. The regulations include requirements for the submission of specific data elements along with patent information, pediatric use information, supplements and amendments, proposed labeling, and specific postmarketing reports.
Respondents to the information collection are sponsors of these applications.
To assist respondents to the information collection we have developed the following forms:
Form FDA 0356h and instructions:
Application to Market a New or Abbreviated New Drug or Biologic for Human Use;
Form FDA 2252 and instructions:
Transmittal of Annual Reports for Drugs and Biologics For Human Use 314.81;
Form FDA 2253 and instructions:
Transmittal of Advertisements and Promotional Labeling For Drugs and Biologics For Human Use; and Forms FDA 3331/3331a: Field Alert Report and Instruction Forms FDA 3542 and 3542a and Instructions: Patent Information Submitted Upon and After Approval of an NDA Supplement; Patent Information Submitted With the Filing of an NDA, Amendment, or Supplement New Draft Form FDA 3898 and Instruction: Drug Master File Individuals requesting printed forms are instructed to contact the FDA Forms Manager by email at formsmanager@
OC.FDA.GOV. Certain fees may be applicable.
Regulations in subpart D 314.100
through 314.170 explain Agency actions on applications and set forth timeframes for FDA review. We are revising the information collection to include provisions established through our Agency user fee programs, most recently authorized under the FDA
Reauthorization Act of 2017. These provisions pertain to review transparency, communications with FDA, dispute resolution, drug safety enhancements, and the allocation of Agency resources to align with these program objectives as agreed to with our stakeholders and set forth in our Performance Goals for Fiscal Years 20182022 Commitment Letters, which
PO 00000

Frm 00034

Fmt 4703

Sfmt 4703

are available from our website at https
www.fda.gov along with more information about FDA user fee programs.
Information collection pertaining to hearing and other administrative proceedings covered in 21 CFR subpart E are approved under OMB control no.
09100191. Unless otherwise noted, information collection pertaining to postmarket safety reporting and associated recordkeeping is approved under OMB control nos. 09100230, 09100291, and 09100645.
Included among the miscellaneous provisions in subpart G 314.410 to 314.445, 314.420 covers information to include in drug master files DMFs.
To assist respondents to this information collection we have prepared templates and resources available from our website at www.fda.gov/drugs/forms-submissionrequirements/drug-master-files-dmfs. As noted above, we have developed new Form FDA 3898 and accompanying instructions on submitting DMFs in accordance with the applicable regulations. In accordance with 314.445, we also develop Agency guidance documents to assist respondents in complying with provisions in part 314. These guidance documents are issued consistent with our good guidance practice regulations at 10.115. To search available FDA
guidance documents, visit our website at https www.fda.gov/regulatoryinformation/search-fda-guidancedocuments. Finally, applications submitted in accordance with subpart H
314.500 through 314.560 pertain to accelerated approval of new drugs for serious or life-threatening illness, and submissions in subpart I 314.600
through 314.650 pertain to approval of new drugs when human efficacy studies are not ethical or feasible. The regulations provide for the submission of specific data elements along with promotional material.
We use the information collection to approve drugs shown to be safe and effective and to implement effective public health monitoring systems. We also use product approval and related patent and exclusivity information to publish the Approved Drug Products with Therapeutic Equivalence Evaluations list the Orange Book.
More information regarding the Orange Book is available from our website at https www.fda.gov/drugs/drugapprovals-and-databases/approveddrug-products-therapeutic-equivalenceevaluations-orange-book.
In the Federal Register of November 16, 2020 85 FR 73057, we published a 60-day notice requesting public
E:FRFM16FEN1.SGM

16FEN1